Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 153

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 153
---
 polar body genome from an MII oocyte into an enucleated donor MII cytoplasm, to increase the number of
oocytes available for the treatment of infertile women, preimplantation methylome screening. There are also breakthrough developments
in science including organ culture systems, induced pluripotent stem cells, embryonic stem cells, spermatogonial stem cells for creation
of functional gametes, but these techniques are not yet ready for human clinical trials.

NewGenIvf also intends to
develop clinically customised interior design concepts for its medical facilities, including improved service rooms, consultation rooms,
reception areas, nutrition food areas, and traditional Chinese medicine (such as acupuncture) facilities.

Increase Brand Awareness and Market Share

NewGenIvf intends to maintain
and strengthen its brand awareness and market share in Asia Pacific. In order to expand its reach and increase patient numbers, NewGenIvf
plans to collaborate with local hospitals, companies, premium hospitality providers and other key players in the ARS industry in Asia
Pacific. Additionally, NewGenIvf intends to increase brand awareness through social media promotions and marketing initiatives, and establishing
its business development team with the goal of attracting new patients and partners across Asia Pacific. Meanwhile, NewGenIvf intends
to provide innovative treatment services to attract more clients. For example, NewGenIvf plans to introduce IVF mental health services,
which allows clients who fail in IVF treatments to access online consultation for further treatment plans such as egg donation and surrogacy.
These new treatments services aim to enable NewGenIvf to attract potential clients. By adopting a comprehensive strategy to expand its
market share, NewGenIvf aims to strengthen its reputation as a long-standing ARS provider and capture additional market share of the growingly
ARS market in Asia-Pacific.

Expand Service Reach Through Acquisitions and Partnerships

Leveraging its reputation
and footprint in its current markets, NewGenIvf intends to expand its reach, services offering and client base through strategic acquisitions
and/or partnerships in Asia Pacific. Acquisitions of or by companies offering similar services could not only allow NewGenIvf to diversify
its client base, but also allow it to benefit from potential economies of scale and increasing efficiency through consolidation. NewGenIvf
could also leverage the acquired or acquiring company’s customer base, reputation and expertise to further improve its offerings
and operations. NewGenIvf intends to focus on ARS providers in Asia Pacific which possess all conventional